Medications

Origin of resistance to lung-cancer drug discovered

Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...

Oncology & Cancer

Melanoma: dabrafenib and trametinib have added benefit

The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with ...

Oncology & Cancer

Researchers uncover up to 100 potential drug targets for cancer

Protein researchers from the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen have used mass spectrometry-based proteomics to uncover a number of proteins that could play a critical role ...

Oncology & Cancer

Evaluating pediatric leukemia treatment

A drug called dasatinib was found to be safe and effective for children with chronic myeloid leukemia, according to a clinical trial published in the Journal of Clinical Oncology.

Oncology & Cancer

Tumor suppressor protein targets liver cancer

Salk Institute scientists, together with researchers from Switzerland's University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth ...

page 5 from 17